INS and type 2 diabetes mellitus: The double-blind Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was initiated to assess the cardiovascular safety of insulin degludec compared with insulin glargine U100.